Tomer M. Mark
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Papers in
- Hematology 106
- Multiple Myeloma Research and Treatments 94
- Hematopoietic Stem Cell Transplantation 15
-
- Protein Degradation and Inhibitors 45
- Cancer therapeutics and mechanisms 9
- Co-authors
- Rubén Niesvizky (49 shared papers)Ajay K. Nooka (11 shared papers)Tamás Masszi (7 shared papers)Katja Weisel (10 shared papers)Vânia Hungria (9 shared papers)Pieter Sonneveld (9 shared papers)Andrew Spencer (10 shared papers)Ivan Špıčka (7 shared papers)
- Journals
- Blood (36 papers)Biology of Blood and Marrow Transplantation (9 papers)Journal of Clinical Oncology (8 papers)Blood Advances (4 papers)Current Hematologic Malignancy Reports (4 papers)
- Partner nations
- United StatesGermanySpain
In The Last Decade
Tomer M. Mark
108 papers receiving 2.4k citations
Tomer M. Mark's Hit Papers
Peers
Comparison fields: 5 of 86
- Hematology 1.9k
- Oncology 1.2k
- Genetics 332
- Molecular Biology 1.5k
- Immunology 253
Countries citing papers authored by Tomer M. Mark
This map shows the geographic impact of Tomer M. Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomer M. Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomer M. Mark more than expected).
Fields of papers citing papers by Tomer M. Mark
This network shows the impact of papers produced by Tomer M. Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomer M. Mark. The network helps show where Tomer M. Mark may publish in the future.
Co-authors
The 25 scholars most cited alongside Tomer M. Mark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1056 |
| 2 | 2000 | 167 | |
| 3 | 2010 | 112 | |
| 4 | 2008 | 79 | |
| 5 | 2007 | 68 | |
| 6 | 2022 | 63 | |
| 7 | 2015 | 48 | |
| 8 | 2007 | 39 | |
| 9 | 2010 | 36 | |
| 10 | 2008 | 33 | |
| 11 | 2020 | 32 | |
| 12 | 2011 | 32 | |
| 13 | 2016 | 31 | |
| 14 | 2014 | 28 | |
| 15 | 2018 | 27 | |
| 16 | 2017 | 27 | |
| 17 | 2013 | 26 | |
| 18 | 2013 | 25 | |
| 19 | 2013 | 24 | |
| 20 | 2013 | 20 |
About Tomer M. Mark
Tomer M. Mark is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 115 papers that have together received 2.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (94 papers), Protein Degradation and Inhibitors (45 papers), Peptidase Inhibition and Analysis (24 papers), Cancer Treatment and Pharmacology (20 papers), Hematopoietic Stem Cell Transplantation (15 papers), Chronic Lymphocytic Leukemia Research (12 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer therapeutics and mechanisms (9 papers). The work is most often cited by research in Hematology (1.9k citations), Oncology (1.2k citations), Genetics (332 citations), Molecular Biology (1.5k citations) and Immunology (253 citations). Tomer M. Mark has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Rubén Niesvizky, Ajay K. Nooka, Tamás Masszi, Katja Weisel, Vânia Hungria, Pieter Sonneveld, Andrew Spencer, Ivan Špıčka, Xiang Qin and María‐Victoria Mateos. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Blood Advances and Current Hematologic Malignancy Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.